about
RAD51C germline mutations in breast and ovarian cancer cases from high-risk familiesGenetic testing for RAD51C mutations: in the clinic and communityContribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the PopulationIdentification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancerInherited Mutations in Women With Ovarian CarcinomaHereditary breast cancer: ever more pieces to the polygenic puzzle.A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancerUtilization of Rad51C promoter for transcriptional targeting of cancer cells.Analyzing association of the XRCC3 gene polymorphism with ovarian cancer risk.Analysis of SLX4/FANCP in non-BRCA1/2-mutated breast cancer families.Single nucleotide polymorphisms in noncoding regions of Rad51C do not change the risk of unselected breast cancer but they modulate the level of oxidative stress and the DNA damage characteristics: a case-control study.Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancerScreening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients.The MTDH (-470G>A) polymorphism is associated with ovarian cancer susceptibility.Analysis of RAD51D in ovarian cancer patients and families with a history of ovarian or breast cancercopy number variation analysis in familial BRCA1/2-negative Finnish breast and ovarian cancer.RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer familiesMutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech RepublicThe GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and PrognosisMutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families.RAD51B in Familial Breast CancerClinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management.Mutation screening of RAD51C in high-risk breast and ovarian cancer families.Gene-panel sequencing and the prediction of breast-cancer risk.UK BRCA mutation testing in patients with ovarian cancer.Genetic characterization of early onset ovarian carcinoma.Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.Molecular genetics of breast and ovarian cancer: recent advances and clinical implicationsHuman DNA helicase HELQ participates in DNA interstrand crosslink tolerance with ATR and RAD51 paralogs.Genomic Biomarkers for Breast Cancer Risk.HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis.RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families.Hereditary breast cancer syndromes and genetic testing.Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplication.Hereditary breast cancer: the era of new susceptibility genes.Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel.Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families.CHEK2 c.1100delC mutation is associated with an increased risk for male breast cancer in Finnish patient population.FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population.
P2860
Q28249994-BDF603F0-92ED-4CE1-89E1-667DAB2635ABQ28253197-E3EFE585-7F04-4770-A2AD-B3A4C7927055Q28266112-0E75EAF8-D9AE-419D-B39C-C4035FF3A702Q28271817-AB65337E-FDD5-4667-9205-E73574D173C0Q30353433-22711448-D0BE-48FA-99F5-14AAAF6D034BQ33356511-52C78964-035E-45E3-86AB-D4972C9671CDQ33663091-9680A09B-6DD5-4ADD-AC16-A93A6AE7E3D5Q33688410-9AEDBD14-19EF-4628-A173-0930E3D6CAC7Q33810401-B3169D53-29E1-416C-8314-51FBEA2502EAQ34188457-84812B94-201C-4025-BF58-34BE47DEC0B0Q34400764-D44F27A9-F967-436F-9E35-18B253C87147Q34408752-045D9393-9373-4C4E-9CB1-72A3AAEB1B6AQ34486808-0940DB0D-6C48-47E4-B253-DEB99DC57B68Q34512485-BC3EC7C7-31FA-43D1-A576-B6452C5C3B28Q34571320-72609E2F-38E7-46B1-861D-203E4BE8CD38Q34964524-CAF608A8-EACA-4D47-8C90-8D3D8189FDA1Q35502165-97DB1670-9341-4E80-8219-1FB4E832E7FFQ35657899-E7EF13EA-C396-455D-BB92-1B5FABB82454Q35793763-99049A9F-4E34-415C-A304-07BBC62255A0Q35889909-8EE2F01B-D6AB-4028-8CF3-A21C2C0FCA98Q36009422-10206E6E-A97F-424F-9CA0-5DEDCBB1226DQ36101775-011BB1B7-362C-4031-B86C-EF29622BB687Q36162179-7FDAC958-DD2A-439E-BDB5-D6FAFBAA3628Q36175072-3538EB98-713E-4E34-95A9-B1E6066A7A2FQ36752065-70869A13-4013-4690-8490-F4C191D6235AQ36908973-AA1D17B7-9B11-4DD7-83F3-E4A294964CBAQ36915151-172673AF-88E7-40BF-A6F9-2FA1FBD60170Q37181547-9DE33144-75B3-410F-9994-A6FD53EF6C17Q37187170-CC62A847-AC7C-47A1-8051-CC18FB51782CQ37242239-E0EB297A-AEDC-4B6C-B50A-199BF14C7384Q37331571-DE5BFEBD-FD95-4515-A720-C7774EF42664Q37690250-F04AE7F2-3228-4048-A581-4788B028CDF8Q38266306-49B8F091-39BE-48B9-A91B-5A6999406B27Q38614203-AAC6BDE9-61F6-4BC1-82D8-A3BACAEF93FCQ38627916-60328CED-2D44-4E45-9394-673D4389FD2CQ39657506-B9D49E65-893F-4EDB-A8E8-309C4AFC5B39Q41034563-AABEE6FE-51B2-4922-AAF8-FE416B9C6E6DQ41111172-06958FAD-87D4-43A1-9F52-ACCB91908B80Q41611265-F087B7D8-A35C-41B2-BDA1-7C78516C2D92Q42683589-62B75E73-8E36-4E11-92B0-A1EACBE648E2
P2860
description
article
@en
im Mai 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2011
@uk
name
RAD51C is a susceptibility gene for ovarian cancer
@en
RAD51C is a susceptibility gene for ovarian cancer
@nl
type
label
RAD51C is a susceptibility gene for ovarian cancer
@en
RAD51C is a susceptibility gene for ovarian cancer
@nl
prefLabel
RAD51C is a susceptibility gene for ovarian cancer
@en
RAD51C is a susceptibility gene for ovarian cancer
@nl
P2093
P2860
P50
P356
P1476
RAD51C is a susceptibility gene for ovarian cancer
@en
P2093
Deborah Thompson
Kaija Holli
Kristiina Aittomäki
Ralf Bützow
P2860
P304
P356
10.1093/HMG/DDR229
P577
2011-05-25T00:00:00Z